Yiyoung Kwon
Overview
Explore the profile of Yiyoung Kwon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
91
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kwon Y, Ahn Y, Yang J, Kim E, Choe Y, Lee S, et al.
Front Pediatr
. 2024 Mar;
11:1242009.
PMID: 38495838
Objective: Biliary atresia (BA) patients develop chronic liver disease after the Kasai operation and are eventually indicated for liver transplantation (LT). The purposes of this study were to analyze long-term...
2.
Kim E, Chon H, Kwon Y, Lee M, Kim M, Choe Y
Ther Drug Monit
. 2024 Jan;
46(4):460-467.
PMID: 38287890
Background: Therapeutic drug monitoring of infliximab (IFX) can improve treatment outcomes; however, the temporal gap between drug concentration monitoring and subsequent availability restricts its practical application. To address this issue,...
3.
Lee H, Kwon Y, Kim E, Ahn S, Choe Y, Kim M
Ann Dermatol
. 2023 Oct;
35(Suppl 1):S107-S111.
PMID: 37853879
Pyoderma gangrenosum is one of the dermatological extra-intestinal manifestations of ulcerative colitis (UC). We report a case of a 26-year-old male patient suffering from relapsed UC with a newly developed...
4.
Kim Y, Kang B, Kim E, Kwon Y, Choe Y, Kim M
Biomedicines
. 2023 Sep;
11(9).
PMID: 37761016
Background: The combination of antitumor necrosis factor-alpha (TNF-α) agents with immunomodulators (IMMs) is a common treatment for pediatric Crohn's disease (CD). Although methotrexate (MTX) can be a first-line medication as...
5.
Kim E, Kwon Y, Choe Y, Kim M, Yoo K
Front Med (Lausanne)
. 2023 Aug;
10:1231066.
PMID: 37614955
Introduction: Acute gastrointestinal graft-versus-host disease (GVHD) is a common life-threatening complication after hematopoietic stem cell transplantation (HCT). We aimed to investigate outcomes according to the clinical, endoscopic, and histologic severity...
6.
Choi S, Kwon Y, Choi S, Lee S, Choe B, Kang B
Front Immunol
. 2023 Jul;
14:1192827.
PMID: 37426637
Introduction: It is well known that infliximab (IFX) trough levels (TLs) are associated with endoscopic healing (EH) in Crohn's disease (CD). We investigated whether IFX TLs are associated with transmural...
7.
Kim E, Kwon Y, Choe Y, Kim M
Therap Adv Gastroenterol
. 2023 May;
16:17562848231170948.
PMID: 37168401
Background: Immunogenicity to antitumor necrosis factor alpha agents, such as infliximab (IFX), may lead to therapeutic failure. Objectives: This study evaluated the relationship between free and total antibodies-to-infliximab (ATIs), trough...
8.
Kwon Y, Kim Y, Choe Y, Kim M
Front Immunol
. 2022 Nov;
13:996875.
PMID: 36389755
Monocytes are involved in the upstream inflammatory process in the immune reaction in inflammatory bowel disease (IBD). Patients with IBD who discontinued biologics have been found to relapse, even after...
9.
Kwon Y, Kim E, Kim Y, Choe Y, Kim M
Biomedicines
. 2022 Oct;
10(10).
PMID: 36289634
Background: This study aims to measure the concentration of cytokines produced during the inflammation process to investigate if there are any differences in response to treatment of pediatric Crohn's disease...
10.
Choi S, Kim E, Kwon Y, Kim M, Choe Y, Choe B, et al.
J Korean Med Sci
. 2022 Sep;
37(37):e282.
PMID: 36163478
Background: Vedolizumab (VDZ) is currently licensed for use in adults for the treatment of inflammatory bowel disease (IBD). We aimed to investigate the clinical course of pediatric-onset IBD following treatment...